Albemarle Pref A ADR: 15min chart sees MACD Death Cross, Bearish Marubozu
PorAinvest
lunes, 20 de octubre de 2025, 1:57 pm ET1 min de lectura
A--
Concurrent Investment Advisors LLC bought a new stake in Agilent Technologies during the second quarter, according to the same MarketBeat alert. The firm bought 2,260 shares of the medical research company's stock, valued at approximately $267,000.
Other hedge funds have also made changes to their positions in the company. Stone House Investment Management LLC purchased a new position in shares of Agilent Technologies in the 1st quarter valued at $30,000. Ransom Advisory Ltd purchased a new position in shares of Agilent Technologies in the 1st quarter valued at $32,000. Central Pacific Bank Trust Division purchased a new position in shares of Agilent Technologies in the 2nd quarter valued at $33,000. Zions Bancorporation National Association UT purchased a new position in shares of Agilent Technologies in the 1st quarter valued at $38,000. Finally, Costello Asset Management INC purchased a new position in shares of Agilent Technologies in the 1st quarter valued at $47,000, as noted in the MarketBeat alert.
Analysts have responded positively to Agilent Technologies' earnings report. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Agilent Technologies. Rothschild Redb raised shares of Agilent Technologies to a "strong-buy" rating. Wall Street Zen raised shares of Agilent Technologies from a "hold" rating to a "buy" rating. Barclays lifted their price target on shares of Agilent Technologies from $125.00 to $150.00 and gave the stock an "equal weight" rating. UBS Group raised shares of Agilent Technologies from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $130.00 to $170.00 — details reported in the MarketBeat alert.
Agilent Technologies, Inc. has a market capitalization of $40.26 billion, a P/E ratio of 33.34, a PEG ratio of 4.63, and a beta of 1.26. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71, and a current ratio of 2.25, according to the MarketBeat alert.
According to the 15-minute chart of Albemarle Pref A ADR, a MACD Death Cross has occurred, accompanied by a Bearish Marubozu at 10/20/2025 13:45. This indicates that the stock price has the potential to continue declining, as sellers are currently dominating the market, and bearish momentum is likely to persist.
Agilent Technologies Inc. (NYSE:A) reported earnings per share (EPS) of $1.37 for the last quarter, meeting analysts' expectations, while revenue increased by 10.1% year-over-year to $1.74 billion, according to a MarketBeat alert https://www.marketbeat.com/instant-alerts/filing-concurrent-investment-advisors-llc-takes-position-in-agilent-technologies-inc-a-2025-10-20/. The company also announced a quarterly dividend of $0.248 per share, with an annualized yield of 0.7%, reflecting a payout ratio of 23.24%.Concurrent Investment Advisors LLC bought a new stake in Agilent Technologies during the second quarter, according to the same MarketBeat alert. The firm bought 2,260 shares of the medical research company's stock, valued at approximately $267,000.
Other hedge funds have also made changes to their positions in the company. Stone House Investment Management LLC purchased a new position in shares of Agilent Technologies in the 1st quarter valued at $30,000. Ransom Advisory Ltd purchased a new position in shares of Agilent Technologies in the 1st quarter valued at $32,000. Central Pacific Bank Trust Division purchased a new position in shares of Agilent Technologies in the 2nd quarter valued at $33,000. Zions Bancorporation National Association UT purchased a new position in shares of Agilent Technologies in the 1st quarter valued at $38,000. Finally, Costello Asset Management INC purchased a new position in shares of Agilent Technologies in the 1st quarter valued at $47,000, as noted in the MarketBeat alert.
Analysts have responded positively to Agilent Technologies' earnings report. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Agilent Technologies. Rothschild Redb raised shares of Agilent Technologies to a "strong-buy" rating. Wall Street Zen raised shares of Agilent Technologies from a "hold" rating to a "buy" rating. Barclays lifted their price target on shares of Agilent Technologies from $125.00 to $150.00 and gave the stock an "equal weight" rating. UBS Group raised shares of Agilent Technologies from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $130.00 to $170.00 — details reported in the MarketBeat alert.
Agilent Technologies, Inc. has a market capitalization of $40.26 billion, a P/E ratio of 33.34, a PEG ratio of 4.63, and a beta of 1.26. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71, and a current ratio of 2.25, according to the MarketBeat alert.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios